This product is specifically designed for promising and innovative entities that require patient capital to
scale up, and for which debt finance is either unattainable or not suitable. The Bank invests by taking up
shareholding in qualifying entities and divesting after a given time. The entity is allowed to involve other
private capital providers where feasible.
The product targets entities with high growth potential and/or socio-economic impact at
pre-revenue, early growth, or growth stage, but deemed unsuitable for conventional debt finance.
UDB will be a shareholder for a maximum of 10 years.